Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Technische Universität Dresden
Deal Size : Inapplicable
Deal Type : Inapplicable
Treosulfan Vs Melphalan Conditioning + PTCy In AML/MDS Allogeneic Transplant
Details : Treosulfan is a Cytotoxic Drug drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 18, 2025
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Technische Universität Dresden
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strategic cornerstone: FDA approves treosulfan for alloHSCT
Details : Grafapex (treosulfan) is now approved by FDA for the treatment of adult and pediatric patients aged 1 year and older with acute myeloid leukemia.
Product Name : Grafapex
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 23, 2025
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement
Details : The fourth amendment adjusts the unpaid regulatory milestone payments upon an FDA approval of Grafapex (treosulfan).
Product Name : Grafapex
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
December 02, 2024
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Methotrexate
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2024
Lead Product(s) : Methotrexate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
UroGen gets Medac License to Develop Novel Mitomycin Formulation for Urothelial Cancers
Details : Under the agreement, UroGen will develop a next-generation novel mitomycin-based formulation, UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, for urothelial cancers.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 17, 2024
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : MC0518
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : MC0518
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Metoject® Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
Details : Primary endpoint of ACR20 response* at 12 weeks was 59.6% in Metoject (Methotrexate) group versus 51.0% in oral MTX group, indicating comparable efficacy. Adverse drug reaction incidence rates in this trial were 25.0% in the Metoject group and 34.0% in t...
Product Name : Metoject
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 26, 2022
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Medexus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update
Details : Trecondyv (treosulfan) is used to prepare patients for blood stem cell transplant. Trecondyv destroys bone marrow cells. This allows for the transplant of new blood stem cells from a donor which leads to the production of healthy blood cells.
Product Name : Trecondyv
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Medexus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 09, 2022
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Antibody part of SYD985 (trastuzumab duocarmazine) binds to HER2 on surface of cancer cell and the ADC is internalized by cell. After proteolytic cleavage of linker, the inactive cytotoxin is activated and DNA damage is induced, resulting in tumor cell d...
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 18, 2022
KEY SERVICES
Reset All
medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.
